GKB OPHTHALMICS LTD. (GKB) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of GKB OPHTHALMICS LTD. ₹79.98, price ₹64.00, upside +25.0%, quality 54 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch GKB OPHTHALMICS LTD. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ₹47.26 – ₹191.05 · fair‑value band ₹39.89 – ₹86.83 · the ₹64.00 price screens below the ₹79.98 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow GKB OPHTHALMICS in your weekly email
Every Wednesday you see whether GKB OPHTHALMICS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
GKB Ophthalmics Limited manufactures and sells ophthalmic lenses in India and internationally. It offers finished and semi-finished glass and plastic lenses. The company was founded in 1981 and is based in Mapusa, India.
Stock analysis
GKB OPHTHALMICS LTD. (GKB) currently trades at ₹64.00, while our model-based Fair Value estimate is ₹79.98, implying the stock looks roughly 20.0% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ₹302.03 per share, and 9 of the 15 models we run sit above the ₹64.00 price.
Bear case: the Earnings-Based group reads lowest at ₹37.16, and 6 of the 15 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹39.89 (bear) to ₹86.83 (bull), the price of ₹64.00 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
GKB OPHTHALMICS LTD. reported revenue of ₹1.5B in FY2026 versus ₹709M in FY2022, a compound +20.4%/yr. Reported net income was ₹12.2M in FY2026, compounding −1.1%/yr from FY2022.
Key figures
Market cap ₹323M (≈ $3.3M) · P/E ratio 26.4 · P/S ratio 0.22 · EPS (TTM) ₹2.42 · Net margin 0.8% · Return on equity 5.4% · Return on assets (EBIT) 0.0% · Operating margin 7.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 35 out of 100 (low confidence).
What moves the price
The share trades about 14% below its 52-week high and 35% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −37% fair-value upside, at 25%, GKB screens cheaper than that median.
Fair Value models
Bear ₹39.89Fair Value ₹79.98Bull ₹86.83
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹1.23 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+36.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.3%
Start year 2021 (pandemic). Over 10 years: +13.0% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.1%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−0.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−0.7%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−0.7% vs −9.0%, picking up
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−3% → 4%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 185 stocks
Beats the industry median on 5/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score54 · Below median
Fair Value upside+10.1% · Above median
Profitability
Return on equity (TTM)5.4% · Below median
Return on assets2.6% · Below median
Net margin (TTM)0.8% · Bottom 25%
Operating margin (TTM)7.8% · Below median
Growth and dividend
Revenue growth−4.0% · Bottom 25%
Balance sheet
Debt / equity0.03× · Below median
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is GKB OPHTHALMICS LTD. (GKB) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ₹79.98 versus a price of ₹64.00, about +25% upside (undervalued).
What is the fair value of GKB?
Our model-based fair value for GKB OPHTHALMICS LTD. is ₹79.98 (as of Sep 24, 2026), built from audited fundamentals. The current price: ₹64.00.
What is the quality score of GKB?
GKB OPHTHALMICS LTD. has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for GKB OPHTHALMICS LTD. (GKB)?
Our model-based price target is the fair value of ₹79.98 (as of Sep 24, 2026) from 15 valuation models. Cautious scenario ₹39.89, optimistic scenario ₹86.83. It is a calculation from audited fundamentals, not an analyst target.
What is the GKB OPHTHALMICS LTD. stock forecast for 2026?
Our models put fair value at ₹79.98, about +25% upside versus a price of ₹64.00 (undervalued). Cautious scenario ₹39.89, optimistic scenario ₹86.83. The calculation is refreshed regularly with new filings.
What is the revenue of GKB OPHTHALMICS LTD. (GKB)?
GKB OPHTHALMICS LTD. reported trailing-twelve-month revenue of about ₹1.5B (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of GKB OPHTHALMICS LTD. (GKB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For GKB OPHTHALMICS LTD. it is ₹79.98 per share (as of Sep 24, 2026), against a price of ₹64.00. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is GKB OPHTHALMICS LTD. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, GKB trades below its calculated fair value: price ₹64.00, fair value ₹79.98, a gap of about +25% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GKB?
No. The price is what the market pays today (₹64.00); the fair value is what the company's own numbers justify (₹79.98). For GKB OPHTHALMICS LTD. the two are ₹15.98 per share apart. That gap is exactly why we show both numbers side by side.
How much is GKB OPHTHALMICS LTD. worth?
The market values GKB OPHTHALMICS LTD. at about ₹323M (market capitalisation, as of Sep 24, 2026). Per share that is ₹64.00; our models calculate a fair value of ₹79.98 per share.
What do the bullish and bearish scenarios say about GKB?
Our models span a range for GKB OPHTHALMICS LTD.: cautious scenario ₹39.89, base ₹79.98, optimistic ₹86.83 per share (as of Sep 24, 2026, price ₹64.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of GKB?
GKB OPHTHALMICS LTD. trades at a price-to-earnings ratio of 26.4 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹79.98 is built from several models across several years. Other multiples: P/B 0.6, P/S 0.2, EV/EBITDA 3.6.
How solid is the balance sheet of GKB OPHTHALMICS LTD. (GKB)?
Balance-sheet figures for GKB OPHTHALMICS LTD. (as of Sep 24, 2026): return on equity 5.4%, debt of 0.03 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is GKB from its 52-week high?
GKB OPHTHALMICS LTD. trades at ₹64.00, about 14% below its 52-week high of ₹74.85 and 35% above the low of ₹47.26 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹79.98 is for.
Which stocks are comparable to GKB OPHTHALMICS LTD.?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is GKB OPHTHALMICS LTD. stock attractive at the current price?
The data as of Sep 24, 2026: price ₹64.00, calculated fair value ₹79.98 (+25%), Quality Score 54/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GKB calculated?
We run GKB OPHTHALMICS LTD. through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹79.98, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. GKB OPHTHALMICS LTD. currently trades 20 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of GKB OPHTHALMICS LTD. (GKB)?
The closing price on Oct 1, 2026 was ₹64.00. Our model-based fair value is ₹79.98, about +25% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with GKB OPHTHALMICS LTD. right now?
Solid quality (54/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (₹39.89 to ₹86.83) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of GKB OPHTHALMICS LTD.
How large is the market capitalisation of GKB OPHTHALMICS LTD. (GKB)?
The market capitalisation of GKB OPHTHALMICS LTD. is ₹323M (≈ $3.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of GKB OPHTHALMICS LTD. (GKB)?
The price-to-sales ratio of GKB OPHTHALMICS LTD. is 0.22 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of GKB OPHTHALMICS LTD. (GKB)?
Earnings per share at GKB OPHTHALMICS LTD. are ₹2.42 (price ÷ EPS = P/E 26.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of GKB OPHTHALMICS LTD. (GKB)?
The net margin of GKB OPHTHALMICS LTD. is 0.8% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of GKB OPHTHALMICS LTD. (GKB)?
The return on equity (ROE) of GKB OPHTHALMICS LTD. is 5.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of GKB OPHTHALMICS LTD. (GKB)?
On an EBIT basis the return on assets of GKB OPHTHALMICS LTD. is 0.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of GKB OPHTHALMICS LTD. (GKB)?
The operating margin of GKB OPHTHALMICS LTD. is 7.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at GKB OPHTHALMICS LTD. (GKB)?
Revenue at GKB OPHTHALMICS LTD. is growing −4.0% versus a year earlier (3y avg +25.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does GKB OPHTHALMICS LTD. (GKB) generate?
The free cash flow of GKB OPHTHALMICS LTD. is −₹48.3M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does GKB OPHTHALMICS LTD. (GKB) carry?
The net debt of GKB OPHTHALMICS LTD. is ₹89.9M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch GKB OPHTHALMICS LTD. in the live analysis
One click puts GKB OPHTHALMICS LTD. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
